EUVIMEDEUVIMED entdecken
EUVIMED · CrossrefZeitschrift

The Lancet HIV

ISSN 2352-3018 · Elsevier BV

Neueste Artikel

  1. Integrating long-acting injectable cabotegravir for HIV prevention into the Brazilian public health system (ImPrEP CAB Brasil): a hybrid type-2 implementation-effectiveness cohort study

    Beatriz Grinsztejn, Thiago Silva Torres, Brenda Hoagland, Carolina Coutinho, Mayara Secco Torres Silva, Iuri Costa Leite, Marcelo Cunha, Monica Derrico, Emilia M Jalil, Sandra Wagner Cardoso, Roberta Trefiglio, Alessandro Farias, Maria Paula G Mourão, José Valdez Madruga, Josué N de Lima, Ronaldo Zonta, Gabrielle O’Malley, Julio Moreira, Keila Simpson, Alex R Rinehart, Nanlesta Pilgrim, Anna Hellstrom, Anne-Isabelle Cameron, Paula Mendes Luz, Raphael J Landovitz, Marcos Benedetti, Cristina Pimenta, Ronaldo Ismério Moreira, Valdilea Gonçalves Veloso, Débora Marra Faber Barreto, Sandro Nazer, Jessica Rodrigues, Carla de Barcellos Rocha, Flavia Lessa, Cristina Jalil, Laylla Monteiro, Josias Freitas, Toni Araújo, Eduardo Carvalheira, Daniel R.B. Bezerra

    Erschienen: 2026-11DOI: 10.1016/s2352-3018(26)00201-8

  2. HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial

    Linda-Gail Bekker, Dhayendre Moodley, Dazon Dixon Diallo, Ishana Harkoo, Godfrey Kigozi, Noah Kiwanuka, Cheryl E Louw, Moelo Malahleha, Lillian Mworeko, Thesla Palanee-Phillips, Ravindre Panchia, Nishanta Singh, Sarah B Puryear, Priyanka Arora, Jared M Baeten, Andrea Brown, Christoph C Carter, Marjorie Imperial, John Ling, Renu Singh, Pamela Wong, Moupali Das, Flavia Matovu Kiweewa

    Erschienen: 2026-09DOI: 10.1016/s2352-3018(26)00112-8

  3. The Lancet HIV Commission on ageing and HIV: a global perspective

    Amy C Justice, Keri N Althoff, A Mark Clarfield, Brenda Crabtree Ramirez, Nathan Ford, Mary-Anne Hartley, Jepchirchir Kiplagat, Grace C Y Lui, Aggrey S Semeere, Marco Vitoria, Stephen Watiti, Tristan J Barber, Till W Barnighausen, Marta Boffito, Mark Brennan-Ing, Jessica Castilho, Stephen R Connor, Claudia Cortes, Giovanni Guaraldi, Meredith Greene, Beatriz Grinsztejn, Catherine Godfrey, Workegegnehu Hailu, Virgilio A Hernandez Ruiz, Javier Hourcade Bellocq, Vanessa Johnson, John Joska, Parastu Kasaie, Oageng Moseki, Nadia Naous, Joel Negin, Daniel Ochieng, Dorothy Onyango, Nicoletta Policek, Yvette Raphael, Julia Rohr, Anat Rosenthal, Enid J Schatz, Melissa C Schnure, Kailey R Seiler

    Erschienen: 2026-08DOI: 10.1016/s2352-3018(26)00058-5

  4. Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial

    Ming J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, Simon Collins, Marcilio Fumagalli, Emanuela Falaschetti, Mohammed Altaf, Timothy Tipoe, Piyumika Godakandaarachi, Julie Fox, Alison Uriel, Amanda Clarke, Sabine Kinloch-de Loes, Sarah Pett, Marta Boffito, Gary Whitlock, Ole S Søgaard, Kyle Ring, Irvine Mangawa, Jesal Gohil, Tamara Elliott, Henrik Nielsen, Jesper Damsgaard Gunst, Chloe Orkin, Rebecca Sutherland, Lisa Hamzah, Paola Cicconi, Graham P Taylor, Jacquie Ujetz, Ishrat Jahan, Helen Brown, Nicola Robinson, Stephen Fletcher, Hanna Box, Kelly E Seaton, Georgia D Tomaras, Margaret E Ackerman, Joshua A Weiner, Anna Kaczynska, Cintia Bittar

    Erschienen: 2026-08DOI: 10.1016/s2352-3018(26)00059-7

  5. Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial

    Eric G Meissner, Moti Ramgopal, Peter J Ruane, William Sanchez, Gordon Crofoot, Jean-Pierre Routy, Cynthia Brinson, Edwin DeJesus, Claudia T Martorell, Marcus Tellez, Yoshiyuki Yokomaku, Mark O’Reilly, Sergio Lupo, Sven Schellberg, Jezer I Lezama-Mora, BumSik Chin, Keith Aizen, Michelle L D’Antoni, Hailin Huang, Kwad Mponponsuo, Jairo M Montezuma-Rusca, Peter Sklar, Martin Rhee, Chien-Ching Hung, Carlos Adon Moreta, Ogechika Alozie, Jonathan Angel, Andrea Antinori, Shauna Applin, Alejandro Arenas-Pinto, Paul Benson, Mezgebe Berhe, Johannes Bogner, Paolo Bonfanti, Indira Brar, Cynthia Brinson, Pedro Cahn, Antonella Castagna, Shu-Hsing Cheng, Bumsik Chin

    Erschienen: 2026-08DOI: 10.1016/s2352-3018(26)00078-0

  6. Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial

    Jürgen K Rockstroh, Sheetal Kassim, Roger Paredes, Christopher Bettacchi, Gary Sinclair, Anchalee Avihingsanon, Nelly Mugo, Jean-Michel Molina, Brenda Crabtree Ramírez, Hiroyuki Gatanaga, Yayun Xu, Stephanie O Klopfer, Tracy L Diamond, Mary Vesnesky, Luisa M Stamm, Michelle C Fox, Mary L Pisculli

    Erschienen: 2026-07DOI: 10.1016/s2352-3018(26)00033-0

  7. Guidance on the clinical management of HIV-1 persistent low-level viraemia on antiretroviral treatment: a scoping review and an international Delphi consensus

    Tommaso Clemente, Arjen J Stam, Olof Elvstam, Anna Maria Geretti, Richard Harrigan, Milosz Parczewski, Nicola E Mackie, Vincenzo Spagnuolo, Marije Hofstra, Francois Venter, Daniel R Kuritzkes, Josep M Llibre, Robert W Shafer, Jonathan Schapiro, Esteban Martinez, Cissy Kityo-Mutuluuza, Monique Nijhuis, Per Björkman, Charlotte Charpentier, Simon Collins, Huldrych F Günthard, Diego Cecchini, Antonella Castagna, Nele Brusselaers, Annemarie MJ Wensing, Diego Cecchini, Anthony D Kelleher, Katharina Grabmeier-Pfistershammer, Linos Vandekerckhove, Ricardo S Diaz, Ivailo Alexiev, Joseph Fokam, Gary Rubin, Richard Harrigan, Wai S Leung, Snježana Židovec-Lepej, Leondios G Kostrikis, Jannik Fonager, Nina Weis, Inka J Aho

    Erschienen: 2026-07DOI: 10.1016/s2352-3018(26)00107-4

  8. Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE

    Emma M Kileel, Carlos D Malvestutto, Markella V Zanni, Emma Davies-Smith, Carl J Fichtenbaum, Jordan E Lake, Janet Lo, Judith A Aberg, Esteban Martinez, Kunjal Patel, Gerald S Bloomfield, Sarah M Chu, Aya Awwad, Marissa R Diggs, Alex B Lu, Sara H Bares, Daniel Berrner, Marek Smieja, Nwora Lance Okeke, Princy Kumar, Esau João, Judith S Currier, Michael T Lu, Matthew P Fox, Alana T Brennan, Pamela S Douglas, Steven K Grinspoon, Heather J Ribaudo

    Erschienen: 2026-05DOI: 10.1016/s2352-3018(25)00354-6

  9. The impact of HIV stigma and discrimination on HIV testing, antiretroviral treatment, and viral suppression in Africa: a pooled analysis of population-based surveys

    Carla M Doyle, Salome Kuchukhidze, James Stannah, Jorge Luis Flores Anato, Yiqing Xia, Carmen H Logie, Arlette Simo Fotso, Mabel Carabali, Gideon Kye-Duodu, Sharmistha Mishra, Anatole Mian, Fern Terris-Prestholt, Oksana Kovtun, Aditya Singh, Jack Stone, Serge Niangoran, Adelina Artenie, Peter Vickerman, Marie-Claude Boily, Mathieu Maheu-Giroux

    Erschienen: 2026-04DOI: 10.1016/s2352-3018(25)00325-x

  10. Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials

    Thumbi Ndung'u, Krista L Dong, Donn J Colby, Steven G Deeks, Mark F Cotton, Karine Dubé, Philip J Goulder, Boris Julg, Moses Nsubuga, Gbolahan Ajibola, Katharine J Bar, Nomonde Bengu, Mutsa Bwakura-Dangarembizi, Marina Caskey, Gabriela Cromhout, Adeodata R Kekitiinwa, William Kilembe, Louise Kuhn, Udom Likhitwonnawut, Nyaradzo M Mgodi, Deborah Persaud, Michael J Peluso, Thomas A Rasmussen, Matthew Romo, Carlo Sacdalan, Wadzanai Samaneka, Roger Shapiro, Ole S Søgaard, Gareth Tudor-Williams, Charity Wambui, Randall Tressler, Sharon R Lewin, Trevor A Crowell, Victoria O Kasprowicz, Lydie Trautmann

    Erschienen: 2026-04DOI: 10.1016/s2352-3018(25)00373-x

  11. Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir–rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study

    Aditya H Gaur, Kristin Baltrusaitis, Edmund V Capparelli, John H Moye, Dwight E Yin, Gaerolwe Masheto, Sarah Buisson, Conn M Harrington, Mark A Marzinke, Elizabeth D Lowenthal, Rachel Scheckter, Andi Ace, Shawn Ward, Ryan Milligan, Kyle Whitson, Jenny Huang, S Y Amy Cheung, Brookie M Best, Ellen Townley, Gilly Roberts, Thomas N Kakuda, Eileen Birmingham, Sisinyana Ruth Mathiba, Linda Aurpibul, Violet Korutaro, Christiana Smith, Faeezah Patel, Evette Moodley, Carolyn Bolton-Moore, Allison L Agwu, Avy Violari, Pradthana Ounchanum, Maxensia Owor, Kulkanya Chokephaibulkit, Andres Camacho-Gonzalez, Mary Paul, Samantha H Fry, Jennifer Jao, Charles Mitchell, Sara Zabih

    Erschienen: 2026-02DOI: 10.1016/s2352-3018(25)00242-5

  12. Identifying priority populations for HIV interventions using acquisition and transmission indicators: a combined analysis of 15 mathematical models from ten African countries

    Romain Silhol, Ross D Booton, Kate M Mitchell, James Stannah, Oliver Stevens, Dobromir Dimitrov, Anna Bershteyn, Leigh F Johnson, Sherrie L Kelly, Hae-Young Kim, Mathieu Maheu-Giroux, Rowan Martin-Hughes, Sharmistha Mishra, Jack Stone, Robyn Stuart, John Stover, Peter Vickerman, David P Wilson, Stefan Baral, Deborah Donnell, Jeffrey W Imai-Eaton, Marie-Claude Boily

    Erschienen: 2026-01DOI: 10.1016/s2352-3018(25)00199-7

  13. Enhancing HIV prevention through systematic community engagement, learning, and response

    Ima John-Dada, Lilian Otiso, Stephen Ayisi Addo, Grace Kumwenda, Raymond Yekeye, Stephen N Kiio, Chimwemwe Mablekisi, Chimika Phiri, Florence R Anam, Nina S Hasen, Barinaada Afirima, Lillian Mworeko, Anne-Isabelle Cameron, Simon Sikwese, Prosper F Njau, Yohane Kamgwira, Sarah N Konopka, Thato Farirai, Richard Chilongosi, Rosemary Mburu, James Odek, Alister Munthali, Gaetan Gatete, Nyanyiwe M Mbeye, Gisele Mujawamariya, Nellie Bristol, Sarah Mwale, Sara M Allinder, Betha O Igbinosun, Charles B Holmes, Solange L Baptiste

    Erschienen: 2026-01DOI: 10.1016/s2352-3018(25)00271-1

  14. ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept study

    Deborah Persaud, Anne Coletti, Bryan S Nelson, Jennifer Jao, Edmund V Capparelli, Diane Costello, Camlin Tierney, Adeodata R Kekitiinwa, Teacler Nematadzira, Boniface N Njau, John Moye, Patrick Jean-Philippe, Violet Korutaro, Annet Nalugo, Tapiwa Mbengeranwa, Tinashe Chidemo, Blandina T Mmbaga, Philoteus A Sakasaka, Mark Cotton, Cheryl Jennings, Carly Hoffmann, Laura Hovind, Yvonne Bryson, Ellen G Chadwick

    Erschienen: 2025-11DOI: 10.1016/s2352-3018(25)00189-4

  15. Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial

    Adrie Bekker, Nicolas Salvadori, Helena Rabie, Samantha du Toit, Kanchana Than-in-at, Maria Groenewald, Shaun Barnabas, Lindee Ganger, Thanchanok Luangcharoenkul, Sirikanya Pingkarawat, Edmund V Capparelli, Andrew Owen, Ratchada Cressey, Samantha Fry, Geraldine Le Roux, Yardpiroon Tawon, Jutatip Kaewmalee, Thamonphat Phitak, Marc Lallemant, Mark F Cotton, Tim R Cressey

    Erschienen: 2025-11DOI: 10.1016/s2352-3018(25)00239-5

  16. Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial

    Jayani Pathirana, Moti Ramgopal, Charlotte Martin, Johannes J Lombaard, Carolina Chahin, Odile Launay, Winai Ratanasuwan, David Greenberg, Carlos G Grijalva, Walter A Orenstein, Angelika Shenkerman, Lori Hall, Doreen Fernsler, Yeonil Kim, Jianing Li, Heather Loryn Platt

    Erschienen: 2025-10DOI: 10.1016/s2352-3018(25)00165-1

Jahrgänge

2026 · 1442025 · 1842024 · 1782023 · 1802022 · 1932021 · 1532020 · 1922019 · 2052018 · 1812017 · 1422016 · 1372015 · 1412014 · 30

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.